男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影

AstraZeneca to build $200m center in China

Updated: 2011-10-12 09:56

By Ma Zhenhuan (China Daily)

  Comments() Print Mail Large Medium  Small 分享按鈕 0

AstraZeneca to build $200m center in China

AstraZeneca PLC workers load blister strips onto a packing line at a factory in Macclesfield, United Kingdom. The UK-based medical company will create 600 jobs by building a new factory in Taizhou, Jiangsu province. [Photo / Bloomberg]

SHANGHAI - AstraZeneca PLC, one of the world's leading pharmaceutical companies, said it would invest $200 million to launch a new manufacturing facility in China to meet growing demand, including in rural areas.

Construction work on the project, in the China Medical City in Taizhou of East China's Jiangsu province, is scheduled for completion by the end of 2013, creating approximately 600 jobs.

This will be London-based AstraZeneca's largest single investment in a manufacturing facility globally. The new plant will produce intravenous and oral solid products, the company said.

"The new facility will significantly enhance our capacity and allow us to meet the growing healthcare demand of the Chinese population, and help us expand into the 900 million (rural) people outside of the big cities and hospitals," Mark Mallon, president of AstraZeneca China, told China Daily in an exclusive interview on Monday.

"It will also allow us to free up some capacity at our existing manufacturing facility in Wuxi, Jiangsu, to bring on more new innovative products that will be launched over the next few years," he added.

The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010, according to market research agency IMS Health Inc, and it is expected to reach $102 billion by 2015.

Mallon said that he believes the Chinese government's focus on healthcare reform and investment in improving healthcare infrastructure and expanding insurance coverage will continue to drive the company's business growth and increase access to quality medicines over the longer term.

AstraZeneca will launch two new products, Faslodex, a treatment for breast cancer, and Onglyza, a new treatment for Type-2 Diabetes, in China this year.

Mallon also mentioned that the company is planning to launch Brilinta, an oral antiplatelet treatment for acute coronary syndrome, next year in China.

With an enhanced manufacturing capacity and the launch of more innovative new medicines, the company is planning to produce more affordable medicines for Chinese patients. It will adopt a multi-channel approach to sell its products to markets beyond big cities and hospitals.

Aside from the medical sales representatives who deal with individual physicians in big cities, the company has developed a team of about 100 customer service representatives who organize educational programs for small clinics and community health centers in China's rural areas.

It will also set up an inbound and outbound call center to reach out to healthcare professionals through phone calls, helping them learn more about AstraZeneca products, he said.

The company, which entered China in 1993, has invested about $500 million in the country, including an innovation center in Zhangjiang, Shanghai.

主站蜘蛛池模板: 绥芬河市| 焉耆| 星座| 永昌县| 文山县| 通许县| 花莲县| 客服| 郧西县| 盐城市| 楚雄市| 舟山市| 张家界市| 临澧县| 瑞丽市| 仁怀市| 正定县| 霸州市| 东至县| 徐闻县| 依安县| 都兰县| 西充县| 阜阳市| 平凉市| 保康县| 开化县| 齐河县| 荃湾区| 都安| 龙游县| 太仆寺旗| 天全县| 井冈山市| 长岛县| 当雄县| 来凤县| 南宫市| 南开区| 华容县| 丹阳市| 武穴市| 河东区| 利辛县| 昌都县| 关岭| 房山区| 永平县| 牟定县| 岗巴县| 洛扎县| 曲沃县| 西宁市| 通州区| 应城市| 甘谷县| 曲靖市| 二连浩特市| 寿阳县| 获嘉县| 公主岭市| 桂林市| 巩留县| 宝兴县| 郸城县| 辰溪县| 普格县| 库车县| 老河口市| 玉门市| 诸暨市| 凤山市| 嵩明县| 波密县| 德兴市| 东山县| 江口县| 察隅县| 永平县| 恩平市| 任丘市| 张掖市|